Inventor
RIGO FRANK
US50 patents
⚠️ This page may combine multiple inventors who share the name “RIGO FRANK”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
IONIS PHARMACEUTICALS INC
38 patentsUS10221414B2Mar 5, 2019
Compositions for modulating C9ORF72 expression
IONIS PHARMACEUTICALS INC14 citations94
US10538763B2Jan 21, 2020
Compounds and methods for modulation of DUX4
IONIS PHARMACEUTICALS INC21 citations93
US9605263B2Mar 28, 2017
Compositions for modulating C9ORF72 expression
IONIS PHARMACEUTICALS INC20 citations92
US9963699B2May 8, 2018
Methods for modulating C9ORF72 expression
IONIS PHARMACEUTICALS INC22 citations90
US10815483B2Oct 27, 2020
Compositions for modulating C9ORF72 expression
IONIS PHARMACEUTICALS INC4 citations84
US10407678B2Sep 10, 2019
Compositions for modulating expression of C9ORF72 antisense transcript
IONIS PHARMACEUTICALS INC6 citations84
US10138482B2Nov 27, 2018
Compositions for modulating C9ORF72 expression
IONIS PHARMACEUTICALS INC11 citations84
US9644207B2May 9, 2017
Compositions and methods for modulating Tau expression
IONIS PHARMACEUTICALS INC10 citations84
US9617539B2Apr 11, 2017
Modulation of UBE3A-ATS expression
IONIS PHARMACEUTICALS INC17 citations78
US11339393B2May 24, 2022
Compositions for modulating C9ORF72 expression
IONIS PHARMACEUTICALS INC2 citations73
US11299737B1Apr 12, 2022
Compounds and methods for modulating SMN2
IONIS PHARMACEUTICALS INC3 citations73
US11732260B2Aug 22, 2023
Compounds and methods for the modulation of amyloid-β precursor protein
IONIS PHARMACEUTICALS INC2 citations72
US10344282B2Jul 9, 2019
Compositions and methods for modulation of IKBKAP splicing
IONIS PHARMACEUTICALS INC2 citations71
US11198867B2Dec 14, 2021
Combinations for the modulation of SMN expression
IONIS PHARMACEUTICALS INC2 citations68
US10533175B2Jan 14, 2020
Compositions and methods for modulating Ataxin 3 expression
IONIS PHARMACEUTICALS INC3 citations67
US12188020B2Jan 7, 2025
Methods for reducing Ataxin-2 expression
IONIS PHARMACEUTICALS INC1 citations64
US10400243B2Sep 3, 2019
Modulation of UBE3A-ATS expression
IONIS PHARMACEUTICALS INC2 citations64
US11926825B2Mar 12, 2024
Compounds and methods for reducing ATXN2 expression
IONIS PHARMACEUTICALS INC1 citations63
US11193128B2Dec 7, 2021
Compositions for modulating expression of C9ORF72 antisense transcript
IONIS PHARMACEUTICALS INC0 citations62
US11155815B2Oct 26, 2021
Compositions and methods for modulating Tau expression
IONIS PHARMACEUTICALS INC1 citations62
US10793855B2Oct 6, 2020
Compositions for modulating expression of C9ORF72 antisense transcript
IONIS PHARMACEUTICALS INC1 citations62
US11459564B2Oct 4, 2022
Modulation of frataxin expression
IONIS PHARMACEUTICALS INC0 citations61
US11260073B2Mar 1, 2022
Compounds and methods for modulating C90RF72
IONIS PHARMACEUTICALS INC0 citations61
US11066668B2Jul 20, 2021
Compositions and methods for modulation of IKBKAP splicing
IONIS PHARMACEUTICALS INC0 citations61
US12275940B2Apr 15, 2025
Conjugated antisense compounds and their use
IONIS PHARMACEUTICALS INC0 citations60
US11725208B2Aug 15, 2023
Conjugated antisense compounds and their use
IONIS PHARMACEUTICALS INC1 citations60
US11162096B2Nov 2, 2021
Methods for modulating expression of C9ORF72 antisense transcript
IONIS PHARMACEUTICALS INC1 citations58
US12502402B2Dec 23, 2025
Compounds and methods for modulating GFAP
IONIS PHARMACEUTICALS INC0 citations57
US11833221B2Dec 5, 2023
Oligomeric compounds for reducing DMPK expression
IONIS PHARMACEUTICALS INC0 citations57
US11786546B2Oct 17, 2023
Compounds and methods for modulating GFAP
IONIS PHARMACEUTICALS INC1 citations57
US11293025B2Apr 5, 2022
Compositions and methods for modulating Ataxin 3 expression
IONIS PHARMACEUTICALS INC0 citations56
US9828602B2Nov 28, 2017
Antisense compounds targeting genes associated with fibronectin
IONIS PHARMACEUTICALS INC1 citations52
US10472634B2Nov 12, 2019
Antisense compounds targeting apolipoprotein E receptor 2
IONIS PHARMACEUTICALS INC0 citations51
US11661601B2May 30, 2023
Methods for modulating FMR1 expression
IONIS PHARMACEUTICALS INC0 citations50
US11236330B2Feb 1, 2022
Antisense compounds and uses thereof
IONIS PHARMACEUTICALS INC0 citations49
US10851371B2Dec 1, 2020
Modulation of SMN expression
IONIS PHARMACEUTICALS INC0 citations44
US9487780B2Nov 8, 2016
Antisense compounds targeting genes associated with fibronectin
IONIS PHARMACEUTICALS INC0 citations42
US10590412B2Mar 17, 2020
Compositions and methods for modulation nucleic acids through nonsense mediated decay
IONIS PHARMACEUTICALS INC0 citations38
BIOGEN MA INC
5 patentsUS9717750B2Aug 1, 2017
Compositions and methods for modulation of SMN2 splicing in a subject
BIOGEN MA INC26 citations93
US9926559B2Mar 27, 2018
Compositions and methods for modulation of SMN2 splicing in a subject
BIOGEN MA INC12 citations84
US10436802B2Oct 8, 2019
Methods for treating spinal muscular atrophy
BIOGEN MA INC13 citations79
US11535848B2Dec 27, 2022
Compositions and methods for modulation of SMN2 splicing in a subject
BIOGEN MA INC1 citations63
US12013403B2Jun 18, 2024
Compositions and methods for detection of SMN protein in a subject and treatment of a subject
BIOGEN MA INC0 citations57